STRATA Skin Sciences, Inc. SSKN recently highlighted findings from a newly published meta-analysis that reinforces the clinical efficacy of its core 308 nm excimer laser technology in treating plaque psoriasis. The review, conducted by academic researchers and published in a peer-reviewed dermatology journal, analyzed multiple clinical studies and pointed to meaningful improvements in disease severity scores following targeted treatment protocols.

For investors, the update adds another layer of third-party validation to STRATA’s XTRAC platform, particularly around optimized, high-fluence, lesion-directed dosing strategies. While the announcement underscores growing academic support for excimer-based UVB therapy, the stock reaction…